Losartan Cost in Utah 2026: Cash Price, Medicaid, Insurance, and Compounding Options

What Is the Cash Price of Losartan in Utah in 2026?

Generic losartan costs approximately $10 per month at most Utah retail pharmacies when purchased without insurance. Prices vary by chain, city, and tablet strength, but a 30-tablet supply of losartan 50 mg consistently falls between $8 and $14 at Walmart, Smith's, Walgreens, and Costco locations in Salt Lake City, Provo, and St. George.

Losartan potassium was first approved by the FDA in 1995 as the first angiotensin II receptor blocker (ARB) for hypertension [1]. Once the patent expired and generics entered the U.S. market, the retail price dropped sharply. The Merck brand (Cozaar) still carries a manufacturer list price near $80 per month, but virtually no Utah patient needs to pay that figure given the availability of multiple FDA-approved generic manufacturers [2].

Price transparency tools show considerable variation even within the same ZIP code. A 90-day supply of losartan 25 mg at a warehouse club such as Costco Pharmacy in Murray, Utah commonly runs $15, $20 total, about $5, $7 per month. Splitting a higher-strength tablet (with prescriber approval) can reduce that further. The FDA's Orange Book lists more than a dozen therapeutically equivalent generic losartan products rated "AB," meaning any can be substituted without additional clinical review [3].

Patients who present a GoodRx or RxSaver coupon at the pharmacy counter typically pay $8, $12 per month for the 50 mg strength. These discount programs are not insurance; they are negotiated pricing contracts between the coupon provider and the pharmacy. Utah law does not restrict their use, and pharmacists are permitted to apply them to losartan prescriptions regardless of whether the patient has active coverage [4].

Does Utah Medicaid Cover Losartan?

Utah Medicaid does not currently list losartan as a covered drug on its Preferred Drug List (PDL), which means standard Medicaid fee-for-service beneficiaries face a prior-authorization requirement or may need a therapeutic alternative. This is a notable gap, given that the JNC guidelines and the 2023 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both recognize ARBs as first-line therapy [5].

Patients enrolled in Utah Medicaid managed-care plans (e.g., Select Health Community Plan, Molina Healthcare of Utah, or UHHP) should check their specific plan formulary, because managed-care formularies may differ from the state PDL. Some managed-care plans do cover losartan as a preferred Tier 1 generic, particularly when prescribed for diabetic nephropathy, an indication backed by the RENAAL trial (N=1,513), which showed a 16% reduction in the composite of doubling of serum creatinine, end-stage renal disease, or death with losartan 100 mg versus placebo (P<0.001) [6].

If a prescriber can document that a patient with type 2 diabetes and proteinuria requires an ARB specifically, a prior-authorization appeal citing the RENAAL data and the ADA Standards of Care recommendation for ARB use in diabetic kidney disease may succeed [7]. Utah Medicaid appeals must be submitted through the Medicaid managed-care plan's utilization management process within 10 business days of a denial.

Low-income patients who do not qualify for Medicaid may access losartan through the Utah Department of Health and Human Services pharmaceutical assistance programs or through federally qualified health centers (FQHCs), many of which purchase losartan under the federal 340B drug discount program. At 340B pricing, losartan cost to the clinic is typically pennies per tablet, and the savings may be passed to the patient.

Is Compounded Losartan Legal in Utah?

Yes. Utah-licensed 503A compounding pharmacies may legally compound losartan for individual patients when a valid prescription is present and a patient-specific clinical rationale supports compounding over the commercially available product [8]. Under the Drug Quality and Security Act (DQSA), 503A pharmacies are state-regulated and may compound drugs that are not essentially a copy of an FDA-approved product or must address a specific patient need (e.g., an alternative dosage form, a different strength not commercially available, or an allergy-driven formula) [9].

Losartan is available commercially in 25 mg, 50 mg, and 100 mg oral tablets. Common compounding rationales in Utah include oral suspension for pediatric patients, lower-strength capsules for patients beginning therapy at below the minimum commercial tablet strength, and topical formulations studied in research contexts. The Utah Division of Occupational and Professional Licensing (DOPL) oversees pharmacy practice; compounding pharmacies must maintain USP 795 compliance for non-sterile preparations [10].

Cost can reach $0 per month for patients enrolled in certain telehealth subscription programs that bundle the compounding pharmacy fee. This is because the telehealth platform may cover dispensing costs as part of a monthly membership. Patients should confirm whether the compounding pharmacy holds an active Utah pharmacy license and whether it sources pharmaceutical-grade losartan API from an FDA-registered supplier [11].

503B outsourcing facilities, by contrast, compound in bulk without patient-specific prescriptions and are FDA-regulated, not state-regulated. No 503B facility currently lists losartan on the FDA's list of bulk drug substances for outsourcing, so all legal compounded losartan in Utah originates from 503A pharmacies operating under a valid individual prescription [12].

How Does Insurance Cover Losartan in Utah?

Most commercial insurance plans in Utah place generic losartan on Tier 1 of their formulary, meaning the patient's copay is typically $0, $10 per 30-day fill. Tier 1 status reflects the drug's long generic history and wide availability. Plans sold on the Utah marketplace (Avenue H or the federal exchange) and large employer plans administered through carriers such as Regence BlueCross BlueShield of Utah, SelectHealth, PEHP, and United Healthcare all commonly tier generic losartan as preferred [13].

The 2023 ACC/AHA guideline for hypertension states: "Angiotensin receptor blockers are recommended as first-line pharmacological therapy for hypertension in patients with chronic kidney disease or diabetes mellitus" [5]. That language often supports formulary placement at the lowest tier for commercial payers, because denying or restricting a guideline-endorsed drug creates utilization management burden without clinical benefit.

Medicare Part D beneficiaries in Utah should verify their specific plan formulary. Generic losartan appears on the formularies of most Part D plans, typically at Tier 1 ($0, $3 copay in the low-income subsidy tier). The CMS Medicare drug pricing database confirms generic losartan as a broadly covered generic [14]. Patients in the coverage gap (the "donut hole") will pay no more than 25% of the negotiated price under current Part D regulations, which at $10/month means approximately $2.50 out of pocket during that phase.

CHIP (Children's Health Insurance Program) in Utah, called CHIP Utah, covers prescription drugs for children. Generic ARBs including losartan are typically covered under CHIP with a small copay ($1, $3 per prescription), which is relevant for pediatric patients with hypertension or nephropathy [15].

What Is the Clinical Evidence Supporting Losartan Prescribing?

Losartan's place in antihypertensive therapy is backed by substantial trial data, which matters because insurance coverage decisions and prescribing volume both follow the evidence base.

The LIFE trial (Lancet 2002, N=9,193) compared losartan 50 to 100 mg to atenolol 50 to 100 mg in hypertensive patients with left ventricular hypertrophy. Losartan produced a 13% relative risk reduction in the primary composite of cardiovascular death, stroke, and myocardial infarction (P=0.021), driven primarily by a 25% reduction in fatal and non-fatal stroke [16]. This was the trial that established ARBs as superior to beta-blockers for stroke prevention in high-risk hypertensive patients.

The RENAAL trial (N=1,513) demonstrated that losartan 100 mg reduced the risk of doubling serum creatinine, end-stage renal disease, or death by 16% in patients with type 2 diabetes and nephropathy compared with placebo (P<0.02) [6]. The FDA subsequently approved losartan for the indication of reducing the rate of progression of renal disease in patients with type 2 diabetes and elevated urinary protein [1].

A meta-analysis published in JAMA (Matchar et al.) comparing ARBs and ACE inhibitors found no significant difference in all-cause mortality between classes, supporting the use of either as first-line therapy based on cost, tolerability, and patient-specific factors [17]. For patients who develop ACE-inhibitor-associated cough (affecting up to 15% of patients), switching to losartan at an equivalent antihypertensive dose typically resolves the cough within 1 to 4 weeks [18].

Losartan's blood pressure-lowering effect is dose-dependent. The standard starting dose is 50 mg once daily, and titration to 100 mg once daily provides additional efficacy in about 20% of patients who do not reach goal at the lower dose [1]. For patients with hepatic impairment, the starting dose should be 25 mg once daily due to reduced first-pass metabolism of the prodrug to its active metabolite, EXP3174 [19].

What Are the Cheapest Ways to Get Losartan in Utah?

The lowest-cost options for losartan in Utah depend on insurance status, income, and whether a compounding option is appropriate.

For uninsured patients, the Walmart $4 generic program lists losartan among its covered drugs; a 30-day supply of 25 mg or 50 mg tablets can cost $4, $9 at Utah Walmart Pharmacy locations [20]. Smith's Food and Drug (Kroger) offers a similar program. These in-store pricing programs require no coupon or enrollment.

GoodRx Gold membership ($9.99 per month per household) brings losartan 50 mg to approximately $8.48 per month at most Utah retail pharmacies based on 2026 pricing data. The membership fee can be offset if a household fills more than two generics per month.

Merck does not offer a patient assistance program (PAP) specifically for losartan because the drug is available as a low-cost generic. However, NeedyMeds and RxAssist both list manufacturer programs and community health center programs where losartan may be dispensed free or at reduced cost to patients below 200% of the federal poverty level [21].

The 340B program, as noted above, allows federally qualified health centers in Utah (including Valley Behavioral Health, Maliheh Free Clinic, and several rural health clinics) to dispense losartan at dramatically reduced prices. Patients who receive care at these clinics and have a household income below a qualifying threshold may receive losartan at no charge [22].

Telehealth providers operating in Utah may bundle losartan prescribing with a compounded formulation through an affiliated 503A pharmacy. The monthly cost in these arrangements can be $0 if the program subsidizes dispensing, or $15, $30 if a specific compounded form (such as an oral liquid) is required. Patients should confirm that the telehealth provider holds an active Utah prescribing license and that the compounding pharmacy is DOPL-registered [23].

How to Get a Losartan Prescription via Telehealth in Utah

Utah law permits synchronous and asynchronous telehealth prescribing for most chronic conditions including hypertension, making losartan prescriptions available without an in-person office visit in many cases [24]. The Utah Telehealth Act (Utah Code 26B-4-701 et seq.) allows licensed practitioners to establish a patient-provider relationship via live video or, in some circumstances, store-and-forward communication.

To receive a losartan prescription via telehealth in Utah, a patient typically needs to:

1. Complete a health history intake including current blood pressure readings, kidney function lab values (creatinine, eGFR), and a list of current medications.
2. Attend a video visit or complete an asynchronous questionnaire with a Utah-licensed prescriber.
3. Receive the prescription electronically to a Utah pharmacy of their choice.

The prescriber will screen for contraindications. Losartan is contraindicated in pregnancy (FDA Pregnancy Category D/X); the drug causes fetal renal dysplasia and should not be prescribed to patients who are pregnant or planning pregnancy without a specific documented risk/benefit discussion [1]. Co-administration with aliskiren is contraindicated in patients with diabetes or an eGFR <60 mL/min/1.73 m2 per FDA labeling [1].

Potassium monitoring matters. Losartan can cause hyperkalemia, particularly in patients with CKD, diabetes, or concurrent use of potassium-sparing diuretics or potassium supplements. A baseline basic metabolic panel and a follow-up panel at 4 to 8 weeks after starting therapy or dose increases is standard practice per the ACC/AHA hypertension guideline [5].

Monitoring Parameters and Follow-Up Expectations

A Utah-based prescriber, whether seen in person or via telehealth, should review blood pressure response 4 to 8 weeks after initiation or dose change. The ACC/AHA 2023 guideline target for most adults is a systolic blood pressure <130 mmHg and diastolic <80 mmHg [5]. Patients with CKD and proteinuria may have a more individualized target depending on the degree of proteinuria and GFR stage [7].

Renal function and electrolytes should be checked 2 to 4 weeks after initiation in patients with CKD stage 3 or higher, and annually in stable patients with normal baseline renal function. Serum creatinine rises of up to 30% above baseline after starting an ARB are considered acceptable and do not require discontinuation per ACC/AHA guidance [5]. Rises above 30% should prompt reassessment for renal artery stenosis or volume depletion [25].

Drug interactions of clinical significance in the Utah primary care setting include concurrent NSAIDs (which blunt the antihypertensive effect and increase nephrotoxicity risk), lithium (losartan reduces renal lithium clearance, raising lithium levels), and combined RAAS blockade with an ACE inhibitor or aliskiren [19].